Supplementary Material: Outcomes of Atezolizumab+Bevacizumab for LRT-Ineligible HCC

figshare admin karger provides supplementary material for a retrospective study of 107 systemic therapy–naïve patients with unresectable hepatocellular carcinoma. The dataset likely contains patient characteristics, diagnostic pathways, and treatment outcomes for first-line atezolizumab plus bevacizumab therapy. The material was last updated on June 1, 2026.

Use Cases

• Analyze diagnostic pathways based on the categorization of patients as LRT-naïve or LRT-experienced.
• Compare clinical outcomes such as objective response rate and disease control rate between patient groups.
• Evaluate progression-free survival based on the reported median of 11.7 months.
• Study the relationship between incidental diagnosis and high-risk metabolic liver disease surveillance.

Strengths

• Includes data from 107 patients, providing a specific cohort size.
• Reports specific clinical metrics, including an objective response rate of 41.8% and a disease control rate of 87.3%.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small, with a total size of 256.1 KB.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of patient records.

Freshness

Last updated 2026-06-01 07:14:54; freshness should be verified.